AtaiBeckley’s EMP-01 Shows Early Promise for Social Anxiety Disorder

AtaiBeckley has reported encouraging Phase IIa results for EMP-01, an investigational treatment for Social Anxiety Disorder (SAD). The double-blind, placebo-controlled trial (NCT06693609) enrolled 71 adults with moderate-to-severe SAD across seven sites in the United Kingdom.

Patients receiving EMP-01 showed a 28.53-point reduction on the Liebowitz Social Anxiety Scale compared with 16.67 points in the placebo group after 43 days. Although the secondary endpoint was not powered for statistical significance, the placebo-adjusted improvement suggested a clinically meaningful effect.

On the CGI-I scale, 49% of EMP-01 patients were rated “much improved” or “very much improved,” versus 15% with placebo. The study also met its primary safety endpoint, with no serious adverse events reported.

EMP-01, an oral derivative related to 3,4‑Methylenedioxymethamphetamine, was administered twice 28 days apart. Researchers say larger trials will be needed to confirm its therapeutic potential.

07-03-2026